A Deeper Look at AIO and Adult Stem Cell Health

Our last article talked about the functions of Adult Stem Cells and how they keep our bodies strong and give us the ability to fight aging and disease. In the next issues we are going to look at the particular reasons why AIO Premium Cellular Health Supplement is vital to that process because of the ingredients it brings to our stem cells.

AIO Premium Cellular Health Supplement contains an incredible blend of the “Best of the Best” in both nature and science. AIO was developed from the studies that state certain Nutraceuticals optimize stem cell functions. As it stands in the nutrition industry, much has been focused on fighting oxidative stress with little efforts towards cell repair, once oxidative stress has been fought. The current products out there are good and they can deliver certain benefits, but they do not go to the heart of the issues after oxidative stress has been addressed. None of them address stem cell health and regeneration.

AIO Premium Cellular Health completed this effort in the industry by creating a nutritional supplement that we believe not only fights oxidative stress but continues to provide what the body needs in order to optimize adult stem cell function. We believe this unique combination is the key to premium cellular health and maintenance. This is why we are seeing the numerous success stories in such a short period of time. We go to the cellular level and address the body’s immune and degenerative issues from within. This amazing supplement supplies us with the necessary ingredients we need in order to fight the symptoms of stress, inflammation, joint pain, and aging issues. It has the ability to regulate body processes such as blood sugar and blood pressure due to the unique, proprietary vitamin and mineral enriched formula.

This delicious, all natural fruit puree is rich in potent antioxidants, which scientific studies suggest fight free radicals and prevent oxidative stress and aging, thereby providing healthy immune system defense support. AIO has been specially formulated to increase bioavailability so that it is easy for your body to assimilate. It is filled with anti-aging and cellular breakthroughs and specifically designed to optimize stem cell functions.

AIO Premium Cellular Health supplement is full of the natural ingredients the body was meant to live on from the beginning. Now instead of eating pounds of fruits daily, you can enjoy this powerful fruit puree that is easy to take and tastes delicious. Just one to four ounces each day provides a concentrated source of nutrients, antioxidants, minerals and Phytonutrients that will have you on your way to premium cellular health and adult stem cell regeneration. Each ounce provides 13,830 mg of whole fruit.

Here is a list of ingredients found in AIO according to their beneficial properties:

• AIO Premium Antioxidant Blend: Amla, Pomegranate, Blueberry, Caja, Camu Camu, Acerola, Acai and Dark Cherry
• AIO Premium Cellular & DNA Health Blend: Vitamin D3, Carnosine, Resveratrol, Green Tea, Uncaria Tomentosa, Vitamin A, Niacin
• AIO Daily Health Blend: Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Vitamin E, Biotin, Potassium, Selenium, Inositol, Lutein, Manganese, Calcium, Chromium

Now that you can see what is in this Power-packed blend, you can better understand why AIO is the answer to taking back your health!

The Medical Staff Behind AIO...

NeoStem Obtains Exclusive Worldwide License for Innovative
Stem Cell Technology and Applications to Heal Chronic
Wounds
May 4, 2009 7:30 AM EDT

NEW YORK, May 4 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex : NBS), which is pioneering the pre-disease
collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an
agreement to license the exclusive worldwide rights to an innovative product and procedure using autologous bone
marrow-derived stem cells to promote the healing of chronic wounds.
The licensed technology, with pending patent applications, has been developed by Vincent Falanga, M.D., Chairman of
the Department of Dermatology and Skin Surgery at Roger Williams Medical Center, Providence, R.I. Dr. Falanga is also
Professor of Dermatology and Biochemistry at Boston University School of Medicine, a Fellow of the American College of
Physicians, and a past President of the Wound Healing Society, the leading scientific organization focused on this
specialty.
Dr. Falanga's stem cell product under development, Primcel, is a mesenchymal stem cell (MSC) product. Early clinical
studies indicate that Primcel can be used to accelerate or jump start healing of chronic wounds. Dr. Falanga's work seeks
to develop a prepackaged product, ready for physician use in a clinical setting, consisting of three applications over a 12-
week period.
Dr. Robin Smith, CEO of NeoStem, said, "We are very pleased to sign this agreement with Dr. Falanga. Acquisition of the
exclusive worldwide rights to this innovative wound healing technology will help advance NeoStem as a leader in the field
of stem-cell tissue regeneration."
Dr. Smith added, "In October 2008, we announced that the U.S. Department of Defense appropriated $800,000 in funds
for NeoStem to evaluate the potential use of adult stem cell therapy for treating wounds suffered by members of the U.S.
military and first responders. We hope this effort will lead to groundbreaking medical findings that ultimately save troops
from amputations and immobilization from injuries sustained while fighting for our country. The award is required to be
distributed to NeoStem by October 2010 and will be in the net amount of $681,000."
"Moreover," she continued, "chronic wounds are a major unmet medical need for both civilians and military personnel. For
example, in 2003, in the United States, 120,000 diabetic patients required treatment for a chronic wound and 75,000
required lower extremity amputations related to unhealed wounds, costing the healthcare system in excess of $4 billion.
Radiation exposure, severe burns, and crush injuries of the bone are other causes of chronic open wounds. Our goal,
through the DOD grant, is to determine if there are multiple sources of autologous stem cells to effectively treat wounds,
and Dr. Falanga's bone marrow procedure is an important step in that direction. Other procedures to be explored may use
mobilized peripheral blood stem cells or VSELs, for example."
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and
store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical
need. The Company has also entered into research and development through the acquisition of a worldwide exclusive
license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to
have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies
to advance its position in the field of stem cell tissue regeneration.
For more information, please visit: www.neostem.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and
involve certain risks and uncertainties. The Company's actual results, including the realization of potential benefits from
the acquisition of its new licensed technology, could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future results to materially differ from the recent results
or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on
Form 10-K for its fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and
Exchange Commission. The Company's further development is highly dependent on future medical and research
developments and market acceptance, which is outside its control.